Financial Publications
In this publications section you can find the Company’s Annual Reports, Quarterly Reports/Statements, our Sustainability Report as well as non-financial statements. Furthermore, there are available presentations held at Investor Relations events and analyst calls.
Financial & Sustainability Reports
Please find below Evotec's financial reports from 1999 onwards as well as respective corresponding documents such as corporate news and analyst presentations.
An overview of all published sustainability-related reports can also be found in the ESG Performance section.
2023
2022
Annual Report
Sustainability Report
Financial Statements
Preliminary FY 2022 Results
Interim Statement 9M 2022
Half-year Report 2022
Interim Statement Q1 2022
2021
Annual Report
Sustainability Report
Financial Statements
Interim Statement 9M
Half-year Report
Interim Statement Q1
2020
Annual Report
Sustainability Report
Financial Statements
Quarterly Statement 9M
Half-year Report
Quarterly Statement Q1
2019
Annual Report
Financial Statements
Separate Non-financial Group Report
Quarterly Statement 9M
Half-year Report
Webcast / Conference Call Regarding the Acquisition of Just.Bio
Quarterly Statement Q1
2018
Annual Report
Financial Statements
Separate Non-financial Group Report
Webcast / Conference Call Regarding the Fiscal Year 2018 Results
Quarterly Statement 9M
Half-year Report
Quarterly Statement Q1
2017
Annual Report
Financial Statements
Separate Non-financial Group Report
Webcast / Conference Call Regarding the Fiscal Year 2017 Results
Quarterly Statement 9M
Half-year Report
Conference Call / Webcast Regarding the Acquisition of Aptuit
Quarterly Statement Q1
2016
Annual Report
Financial Statements
Conference Call / Webcast Regarding Strategic Collaboration with Celgene
Quarterly Statement Q3
Conference Call / Webcast Regarding the Offer to Acquire Cyprotex
Half-year Report
Quarterly Statement Q1
2015
Annual Report
Financial Statements
Nine-month Interim Report
Half-year Report
First Quarter Report
2014
Annual Report
Financial Statements
Conference Call / Webcast Announcing Negotiations on Major Collaboration with Sanofi
Nine-month Interim Report
Half-year Report
First Quarter Report
2013
Annual Report
Financial Statements
Nine-month Interim Report
Half-year Report
First Quarter Report
2012
Annual Report
Financial Statements
Half-year Report
First Quarter Report
2011
Annual Report
Financial Statements
Third Quarter Report
Conference Call / Webcast Announcing License Agreement with Roche
Half Year Report
Conference Call and Webcast Announcing the Acquisition of Compound Focus, Inc.
First Quarter Report
Conference Call and Webcast Announcing the Acquisition of Kinaxo
2010
Annual Report
Financial Statements
Conference Call and Webcast Announcing the Alliance With MedImmune
Third Quarter Report
Half Year Report
Conference Call and Webcast Announcing the Acquisition of DeveloGen
First Quarter Report
2009
Annual Report
Financial Statements
Third Quarter Report
Half Year Report
First Quarter Report
2008
Annual Report
Financial Statements
Third Quarter Report
Half Year Report
First Quarter Report
2007
Annual Report
Financial Statements
Third Quarter Report
Half Year Report
First Quarter Report
2006
Annual Report
Financial Statements According to HGB
Third Quarter Report
Second Quarter Report
First Quarter Report
2005
Annual Report
Third Quarter Report
Second Quarter Report
First Quarter Report
New Segmental P&L Statements
2004
Annual Report
Third Quarter Report
Second Quarter Report
First Quarter Report
2003
Annual Report
Third Quarter Report
Second Quarter Report
First Quarter Report
2002
Annual Report
Third Quarter Report
Second Quarter Report
First Quarter Report
2001
Annual Report
Third Quarter Report
Second Quarter Report
First Quarter Report
2000
Annual Report
Third Quarter Report
Second Quarter Report
First Quarter Report
Oxford Asymmetry International plc 2000 Interim Statement
1999
Annual Report
Third Quarter Report
Oxford Asymmetry International plc Annual Report 1999
SEC Filings
On this page you can find all documents published in realation to our public listing on NASDAQ.
For the original documents published on the EDGAR ("Electronic Data Gathering, Analysis, and Retrieval") database of the U.S. Securities and exchange commission ("SEC"), please use the below link.
Three shareholders, Novo Holdings A/S, T. Rowe Price Group Inc. and Mubadala Investment Company, currently hold more than 5% of the shares of Evotec SE. The free float according to the definition of the Frankfurt Stock Exchange is approx. 72% according to our estimates (Evotec: 09/2023).
IR & ESG Presentations
Downlaods
- Company Presentation 4.275 MB
- Evotec Corporate Governance Roadshow February 2023 1.639 MB
- Analyst Call Preliminary Full-year Results 2022 4.482 MB
- Evotec Capital Markets Day, 05 June 2023 8.371 MB
- Analyst Call Business Update First Half-year 2023 (20 July 2023) 847.14 KB
- Analyst Call Q2/6M 2023 (29 August 2023) 5.092 MB
Non-financial Statements
- Presentation Capital Markets Day, PDF
20 April 2021 - Presentation Annual General Meeting 2021, PDF
15 June 2021 (in German) - Analyst Presentation H1 2021, PDF
11 August 2021 - Analyst Presentation Q3/9M 2021
11 November 2021 - Presentation Corporate Governance Roadshow
February 2022 - Presentation Capital Markets Day
2 March 2022 - Analyst Presentation Full-year 2021
12 April 2022 - Analyst Presentation Q1 2022
11 May 2022 - Presentation Annual General Meeting 2022
22 June 2022 - Presentation Analyst Call H1 2022
11 August 2022 - Presentation Capital Markets Day
2 November 2022 - Analyst Presentation Q3/9M 2022
9 November 2022 - Analyst Presentation Q3/9M 2023, PDF
08 November 2023 - Presentation Capital Markets Day, PDF
15 November 2023
Contact Our Experts
